Cooper's Decision to Retain CooperSurgical Removes Key Bull Case, UBS Says

MT Newswires Live

17 hours ago

Cooper's (COO) "disappointing" Q3 and conclusion of a strategic review to retain CooperSurgical cross out main driver for an upside, UBS Securities said in a note emailed Thursday.

The strategic review, launched in December 2025, included an evaluation of CooperSurgical's potential sale, and management ultimately concluded that continued ownership of the business was in shareholders' best interests, the company said Wednesday.

Cooper is now shifting focus toward $2 billion to $3 billion of buybacks and cash-flow generation.

Cooper's Q3 print reflected stagnant growth across the business and unfavorable contact lens inventory dynamics, which will continue in Q4, UBS said.

UBS lowered its 2026 revenue estimate to $4.24 billion from $4.31 billion and EPS estimate to $4.51 from $4.60.

UBS maintained its neutral rating and lowered its price target to $66 from $75.

Price: 55.14, Change: -8.34, Percent Change: -13.14

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/news/2666951873"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2666951873\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2666951873?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-11 03:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2666951873","market":"sh","top_or_hot":-1,"title":"Cooper's Decision to Retain CooperSurgical Removes Key Bull Case, UBS Says","media":"MT Newswires Live","content":"<html><body><p> Cooper's (COO) \"disappointing\" Q3 and conclusion of a strategic review to retain CooperSurgical cross out main driver for an upside, UBS Securities said in a note emailed Thursday.</p><p>The strategic review, launched in December 2025, included an evaluation of CooperSurgical's potential sale, and management ultimately concluded that continued ownership of the business was in shareholders' best interests, the company said Wednesday.</p><p>Cooper is now shifting focus toward $2 billion to $3 billion of buybacks and cash-flow generation.</p><p>Cooper's Q3 print reflected stagnant growth across the business and unfavorable contact lens inventory dynamics, which will continue in Q4, UBS said.</p><p>UBS lowered its 2026 revenue estimate to $4.24 billion from $4.31 billion and EPS estimate to $4.51 from $4.60.</p><p>UBS maintained its neutral rating and lowered its price target to $66 from $75.</p><p>Price: 55.14, Change: -8.34, Percent Change: -13.14</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cooper's Decision to Retain CooperSurgical Removes Key Bull Case, UBS Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCooper's Decision to Retain CooperSurgical Removes Key Bull Case, UBS Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-11 03:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Cooper's (COO) \"disappointing\" Q3 and conclusion of a strategic review to retain CooperSurgical cross out main driver for an upside, UBS Securities said in a note emailed Thursday.</p><p>The strategic review, launched in December 2025, included an evaluation of CooperSurgical's potential sale, and management ultimately concluded that continued ownership of the business was in shareholders' best interests, the company said Wednesday.</p><p>Cooper is now shifting focus toward $2 billion to $3 billion of buybacks and cash-flow generation.</p><p>Cooper's Q3 print reflected stagnant growth across the business and unfavorable contact lens inventory dynamics, which will continue in Q4, UBS said.</p><p>UBS lowered its 2026 revenue estimate to $4.24 billion from $4.31 billion and EPS estimate to $4.51 from $4.60.</p><p>UBS maintained its neutral rating and lowered its price target to $66 from $75.</p><p>Price: 55.14, Change: -8.34, Percent Change: -13.14</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7016","symbol_name":"应用软件","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2666951873","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2666951873","pubTimestamp":1789068878,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cooper's  \"disappointing\" Q3 and conclusion of a strategic review to retain CooperSurgical cross out main driver for an upside, UBS Securities said in a note emailed Thursday.The strategic review, launched in December 2025, included an evaluation of CooperSurgical's potential sale, and management ultimately concluded that continued ownership of the business was in shareholders' best interests, the company said Wednesday.Cooper is now shifting focus toward $2 billion to $3 billion of buybacks and cash-flow generation.Cooper's Q3 print reflected stagnant growth across the business and unfavorable contact lens inventory dynamics, which will continue in Q4, UBS said.UBS lowered its 2026 revenue estimate to $4.24 billion from $4.31 billion and EPS estimate to $4.51 from $4.60.UBS maintained its neutral rating and lowered its price target to $66 from $75.Price: 55.14, Change: -8.34, Percent Change: -13.14","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7016":"应用软件","LU2272731600.USD":"Allianz Global Intelligent Cities AM Dis USD","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","BK4588":"碎股","LU2272731782.SGD":"Allianz Global Intelligent Cities AM Dis H2-SGD","COO":"库珀医疗","BK4585":"ETF&股票定投概念","BK4198":"医疗保健用品","COO.AU":"Corum Group Ltd","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","LU1992135399.USD":"Allianz Global Intelligent Cities AT Acc USD","LU1992135472.HKD":"ALLIANZ GLOBAL INTELLIGENT CITIES \"AT\" (HKD) ACC"},"translate_title":"瑞银表示，库珀保留库珀外科的决定消除了关键的牛市案例","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COO":1.5,"COO.AU":1},"content_text":"Cooper's (COO) \"disappointing\" Q3 and conclusion of a strategic review to retain CooperSurgical cross out main driver for an upside, UBS Securities said in a note emailed Thursday.The strategic review, launched in December 2025, included an evaluation of CooperSurgical's potential sale, and management ultimately concluded that continued ownership of the business was in shareholders' best interests, the company said Wednesday.Cooper is now shifting focus toward $2 billion to $3 billion of buybacks and cash-flow generation.Cooper's Q3 print reflected stagnant growth across the business and unfavorable contact lens inventory dynamics, which will continue in Q4, UBS said.UBS lowered its 2026 revenue estimate to $4.24 billion from $4.31 billion and EPS estimate to $4.51 from $4.60.UBS maintained its neutral rating and lowered its price target to $66 from $75.Price: 55.14, Change: -8.34, Percent Change: -13.14","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}